Reducing risk factors is a useful way to counteract diseases. The prevalence of Alzheimer's disease (AD) in the US is often quoted as 6.9 million out of 333 million people, or 2.1%. It is around 0.7% in the UK, 0.9% in Denmark, and worldwide the estimate is 0.5%. Alongside risk factor reduction, the Centers for Medicare and Medicaid Services could strengthen the US fight against AD by reconsidering its October 2023 decision to liberalize reimbursement of amyloid PET scans, or better yet, advise replacing these non-specific scans with FDG-PET, which shows what AD is really about: impaired regional brain function.
LeahyTPSimpsonASammonC, et al.Estimating the prevalence of diagnosed Alzheimer disease in England across deprivation groups using electronic health records: a clinical practice research datalink study. BMJ Open2023; 13: e075800.
4.
TaudorfLNørgaardAIslamoskaS, et al.Declining incidence of dementia: a national registry-based study over 20 years. Alzheimers Dement2019; 15: 1383–1391.
WoltersFJChibnikLBWaziryR, et al.Twenty-seven-year time trends in dementia incidence in Europe and the United States: the Alzheimer Cohorts Consortium. Neurology2020; 95: e519–e531.
7.
BrookmeyerRGraySKawasC. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health1998; 88: 1337–1342.
8.
SilveySSterlingRKFrenchE, et al.A possible reversible cause of cognitive impairment: undiagnosed cirrhosis and potential hepatic encephalopathy in patients with dementia. Am J Med2024; 137: 1082–1087.
9.
KnopmanDSPetersenRCJackCRJr. A brief history of “Alzheimer disease": multiple meanings separated by a common name. Neurology2019; 92: 1053–1059.
10.
JackCRJrAlbertMSKnopmanDS, et al.Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 257–262.
11.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 263–269.
12.
JackCRJrBennettDABlennowK, et al.NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement2018; 14: 535–562.
13.
JackCRJrAndrewsJSBeachTG, et al.Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement2024; 20: 5143–5169.
14.
MurayamaSSaitoY. Neuropathological diagnostic criteria for Alzheimer's disease. Neuropathology2004; 24: 254–260.
15.
VillemagneVLKlunkWEMathisCA, et al.Aβ imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. Eur J Nucl Med Mol Imaging2012; 39: 209–219.
16.
SurmakAJWongKPColeGB, et al.Probing estrogen sulfotransferase-mediated inflammation with [11C]-PiB in the living human brain. J Alzheimers Dis2020; 73: 1023–1033.
17.
Høilund-CarlsenPFAlaviABarrioJR. PET/CT/MRI in clinical trials of Alzheimer's disease. J Alzheimers Dis2024; 101: S579–S601.
